Agile Therapeutics, Inc , a women’s healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States.
infoAgile Therapeutics is a micro cap stock with a total market cap of 4.06M.
infoThey trade on the NASDAQ and had their IPO 9 years and 3 months ago.
infoAgile Therapeutics currently employs 22 people.
infoAs of Wednesday, Aug 23 2023, Agile Therapeutics’s share price is $2.11.
News Relating to Agile Therapeutics
GlobeNewsWire
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
Wednesday Jul 26 2023 at 08:30
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report second quarter 2023 financial results before the market open on Wednesday, August 9, 2023.
Seeking Alpha
Agile Therapeutics, Inc. (AGRX) Q1 2023 Earnings Call Transcript
Friday May 12 2023 at 19:09
Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Matt Riley – Head, Investor Relations Al Altomari – Chairman & Chief Executive Officer Conference Call Participants Oren Livnat – H.C. Wainwright Operator Good day, and thank you for standing by.
GlobeNewsWire
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
Monday May 08 2023 at 08:00
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report first quarter 2023 financial results after the market close on Thursday, May 11, 2023.
GlobeNewsWire
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
Tuesday Mar 21 2023 at 09:05
Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
Zacks Investment Research
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
Thursday Feb 09 2023 at 09:48
TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.
GlobeNewsWire
Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference
Thursday Dec 01 2022 at 08:30
PRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022. Chairman and Chief Executive Officer Al Altomari will present a corporate overview at the conference on Monday, December 5 at 3:20 p.m. ET.
Seeking Alpha
Agile Therapeutics, Inc. (AGRX) Q3 2022 Earnings Call Transcript
Monday Nov 07 2022 at 18:59
Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q3 2022 Results Conference Call November 7, 2022 4:30 PM ET Company Participants Matthew Riley – Head of Investor Relations Alfred Altomari – Chairman and Chief Executive Officer Amy Welsh – Chief Commercial Officer Jason Butch – Chief Accounting Officer Conference Call Participants Oren Livnat – H.C. Wainwright Nazibur Rahman – Maxim Group LLC Operator Good afternoon, and welcome to the Agile Therapeutics Third Quarter 2022 Financial Results Conference Call.
GlobeNewsWire
Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022
Wednesday Oct 26 2022 at 08:30
Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
GlobeNewsWire
Agile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Tuesday Sep 06 2022 at 08:30
PRINCETON, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced that Chairman and Chief Executive Officer Al Altomari and Vice President of Marketing Amy Welsh will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 in New York, NY. Details on the Company presentation are as follows:
24/7 Wall Street
These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)
Friday Sep 02 2022 at 20:22
Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).
Seeking Alpha
Agile Therapeutics, Inc. (AGRX) CEO Al Altomari on Q2 2022 Results – Earnings Call Transcript
Thursday Aug 11 2022 at 19:17
Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Matt Riley – Head, IR Al Altomari – Chairman and CEO Amy Welsh – VP, Marketing Conference Call Participants Oren Livnat – H.C. Wainright Operator Good afternoon, and welcome to the Agile Therapeutics Second Quarter 2022 Financial Results Conference Call.
GlobeNewsWire
Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022
Thursday Jul 28 2022 at 08:05
Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
PennyStocks
Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch
Monday Jul 11 2022 at 09:25
More penny stocks to watch under $1 The post Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
What to Know About Buying Penny Stocks on July 7th
Thursday Jul 07 2022 at 07:00
Here’s what you need to know about trading penny stocks on July 6th The post What to Know About Buying Penny Stocks on July 7th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving
Monday Jun 27 2022 at 09:05
Penny stocks to watch with news The post Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GlobeNewsWire
Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference
Tuesday May 17 2022 at 08:01
PRINCETON, N.J., May 17, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference taking place May 23-May 26, 2022 in Miami, FL. Details on the Company presentation are as follows:
Seeking Alpha
Agile Therapeutics, Inc. (AGRX) CEO Al Altomari on Q1 2022 Results – Earnings Call Transcript
Thursday May 12 2022 at 20:58
Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q1 2022 Results Conference Call May 12, 2022 4:30 PM ET Company Participants Matt Riley – Head, IR Al Altomari – Chairman, CEO Dennis Reilly – CFO Conference Call Participants Oren Livnat – H.C. Wainwright Operator Good afternoon, and welcome to the Agile Therapeutics’ First Quarter 2022 Financial Results Conference Call.
Pulse2
Agile Therapeutics (AGRX) Stock: 1-For-40 Reverse Stock Split Goes Into Effect
Wednesday Apr 27 2022 at 05:36
A 1-for-40 reverse stock split of Agile Therapeutics, Inc. (Nasdaq: AGRX) has gone into effect. These are the details.
PennyStocks
Hot Penny Stocks to Buy Today? 3 For Your Watchlist
Tuesday Apr 26 2022 at 09:30
Here’s what you need to know about trading penny stocks on April 26th The post Hot Penny Stocks to Buy Today? 3 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
Best Penny Stocks Today? 4 To Buy For Under $1 According To Reddit
Monday Apr 18 2022 at 12:38
Popular Reddit penny stocks to watch under $1. The post Best Penny Stocks Today?
PennyStocks
Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes
Wednesday Apr 13 2022 at 09:28
Here’s what you need to know about trading penny stocks on April 13th The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today
Tuesday Apr 12 2022 at 15:02
Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Seeking Alpha
Agile Therapeutics: Twirla’s Lackluster Launch Forces Me To Change My Strategy
Monday Apr 04 2022 at 13:10
Agile Therapeutics has finished its first full year as a commercial company and was able to establish an attractive growth curve for Twirla in several metrics.
Seeking Alpha
Agile Therapeutics, Inc.’s (AGRX) CEO Al Altomari on Q4 2021 Results – Earnings Call Transcript
Wednesday Mar 30 2022 at 19:47
Agile Therapeutics, Inc.’s (AGRX) CEO Al Altomari on Q4 2021 Results – Earnings Call Transcript
Zacks Investment Research
Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates
Wednesday Mar 30 2022 at 18:48
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of -17.65% and 3.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Agile Therapeutics to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Wednesday, March 30, 2022
Monday Mar 07 2022 at 08:01
Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
GlobeNewsWire
Agile Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Wednesday Jan 05 2022 at 08:03
PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 7:30 a.m. ET.
GlobeNewsWire
Agile Therapeutics to Present at the Biotech Showcase and H.C. Wainwright BioConnect Virtual Conferences
Wednesday Jan 05 2022 at 08:01
PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will present at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022.
PennyStocks
Top Penny Stocks For Your Under $1 List Right Now
Wednesday Dec 01 2021 at 09:22
Check these Under $1 penny stocks out for your watchlist The post Top Penny Stocks For Your Under $1 List Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Seeking Alpha
Agile Therapeutics: Worst Is Over
Saturday Nov 13 2021 at 23:56
After trading down from $2.86/share to $.75/share so far this year, Agile’s share price is reflecting worse-case scenario. Despite the market sell-off, Agile’s business is actually ramping up.
Agile Therapeutics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Agile Therapeutics’s Altman Z-score is -52.4 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Agile Therapeutics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Agile Therapeutics.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Agile Therapeutics’s Income Quality of 0.66 is in line with its Industry Group of 0.69 (-4.3% lower)
Agile Therapeutics’s Income Quality of 0.66 is in line with its Major Industry Group of 0.71 (-7.0% lower)
Agile Therapeutics’s Income Quality of 0.66 is lower than its Sector of 0.75 (-12.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Agile Therapeutics’s Current Ratio of 0.76 is lower than its Industry Group of 4.76 (-84.0% lower)
Agile Therapeutics’s Current Ratio of 0.76 is lower than its Major Industry Group of 4.32 (-82.4% lower)
Agile Therapeutics’s Current Ratio of 0.76 is lower than its Sector of 2.6 (-70.8% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.1 & -1.27)
Cannot compare a negative PE Ratio (-0.1 & -1.1)
Cannot compare a negative PE Ratio (-0.1 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Cannot compare a negative PB Ratio (-0.34 & 1.34)
Cannot compare a negative PB Ratio (-0.34 & 1.4)
Cannot compare a negative PB Ratio (-0.34 & 1.62)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Agile Therapeutics’s ROE of 3.53 is greater than its Industry Group of -0.44 (902.3% greater)
Agile Therapeutics’s ROE of 3.53 is greater than its Major Industry Group of -0.38 (1028.9% greater)
Agile Therapeutics’s ROE of 3.53 is greater than its Sector of -0.03 (11866.7% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Agile Therapeutics’s ROCE of 9.6 is greater than its Industry Group of -0.42 (2385.7% greater)
Agile Therapeutics’s ROCE of 9.6 is greater than its Major Industry Group of -0.37 (2694.6% greater)
Agile Therapeutics’s ROCE of 9.6 is greater than its Sector of -0.04 (24100.0% greater)
Derived from SEC.GOV filing dataopen_in_new